Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Peppermint oil 0.2ml gastro-resistant capsules
0102000T0AAAAAA
|
Peppermint oil | Peppermint oil | Gastro-Intestinal System | 83,402 |
|
Peppermint oil 0.2ml gastro-resistant modified-release caps
0102000T0AAAFAF
|
Peppermint oil | Peppermint oil | Gastro-Intestinal System | 24,859 |
|
Colpermin gastro-resistant modified-release capsules
0102000T0BBAAAF
|
Colpermin | Peppermint oil | Gastro-Intestinal System | 17,956 |
|
Mintec 0.2ml gastro-resistant capsules
0102000T0BCAAAA
|
Mintec | Peppermint oil | Gastro-Intestinal System | 7,416 |
|
PepperMinn 0.2ml gastro-resistant capsules
0102000T0BKAAAA
|
PepperMinn | Peppermint oil | Gastro-Intestinal System | 577 |
|
Apercap 0.2ml gastro-resistant capsules
0102000T0BIAAAA
|
Apercap | Peppermint oil | Gastro-Intestinal System | 252 |
|
Peppermint oil liquid
0102000T0AAABAB
|
Peppermint oil | Peppermint oil | Gastro-Intestinal System | 8 |
|
Colomint 0.2ml gastro-resistant capsules
0102000T0BJAAAA
|
Colomint | Peppermint oil | Gastro-Intestinal System | 7 |
|
ColoPep 0.2ml gastro-resistant capsules
0102000T0BMAAAA
|
ColoPep | Peppermint oil | Gastro-Intestinal System | 1 |
|
Buscomint 0.2ml gastro-resistant capsules
0102000T0BLAAAA
|
Buscomint | Peppermint oil | Gastro-Intestinal System | No data available |
|
Equilon Herbal 0.2ml gastro-resistant capsules
0102000T0BGAAAA
|
Equilon Herbal | Peppermint oil | Gastro-Intestinal System | No data available |
|
Purosure Peppermint oil 0.2ml gastro-resistant capsules
0102000T0BNAAAA
|
Purosure (Peppermint) | Peppermint oil | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.